All Stocks/Healthcare/OGN

Organon & Co.

OGN
HealthcareDrug Manufacturers - General Website
Price ChartPowered by TradingView
Ask about OGNAI research agent
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
D.E. Shaw
David Shaw
3.40M$24.41MNEW
Citadel
Ken Griffin
2.79M$19.97MNEW
Point72
Steve Cohen
686K$4.92MNEW
Marshall Wace440K$3.15MNEW
Politicians who traded OGNFrom Senate & House PTRs
PoliticianDateTypeAmount
Kevin Hern
R-OK
2026-08-05sale$1k – $15k
About Organon & Co.

Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies. Its primary focus areas include women’s health, biosimilars, and established brands, addressing key therapeutic needs in reproductive health, dermatology, and chronic disease management. The company offers products such as contraceptives, menopause treatments, fertility solutions, and oncology biosimilars, alongside a range of mature branded medicines for pain, respiratory conditions, and cardiovascular disorders. Organon & Co. operates across major geographies, with significant presence in Europe, Canada, the United States, Asia Pacific, and Japan. It emphasizes research and development to advance therapies in women’s health and biosimilars, while maintaining a strong lineup of established products that provide reliable treatment options worldwide. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. plays a vital role in the pharmaceutical sector by bridging innovation with accessible healthcare solutions for diverse patient populations.

CEO
Mr. Joseph T. Morrissey Jr.
Employees
10,000
Quick Facts
Exchange–
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap–
Key Dates

Earnings calendar coming soon. Subscribe to get notified when OGN reports next.

Get earnings alerts →